Semaglutide: What the Research Says
A GLP-1 receptor agonist backed by a decade of randomized clinical trials. Here's the published science — what the evidence shows, and where it stops.
What is semaglutide?
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone your gut releases after eating. It was developed by Novo Nordisk and first approved by the FDA in 2017 under the brand name Ozempic for type 2 diabetes, then in 2021 as Wegovy for chronic weight management.
The molecule shares roughly 94% sequence homology with native GLP-1, with targeted modifications that extend its half-life to around seven days. That's why it can be dosed once weekly rather than several times daily, which is how native GLP-1 would need to be delivered.
Compounded semaglutide uses the same active ingredient but is prepared by licensed U.S. compounding pharmacies outside the brand-name FDA-approval pathway, under federal 503A or 503B compounding rules. It is not FDA-approved; it is legally prepared under a separate regulatory framework that has existed for decades.
How it works (mechanism of action)
Binds and activates GLP-1 receptors
Semaglutide selectively activates GLP-1 receptors found in the pancreas, brain, and gastrointestinal tract. The activation cascade is dose-dependent and has been characterized across multiple tissue types in published pharmacology literature (Knudsen & Lau, Frontiers in Endocrinology, 2019).
Central nervous system signaling
GLP-1 receptors in the hypothalamus and brainstem modulate satiety and reward-based eating. Functional MRI studies (e.g., van Bloemendaal et al., Diabetes, 2014) have demonstrated reduced activation of food-reward circuits in patients on GLP-1 agonists.
Slowed stomach-emptying rate
Semaglutide meaningfully slows gastric emptying, prolonging the sensation of fullness after meals. This effect attenuates with chronic use (tachyphylaxis) but appears to persist at a reduced level even after months of treatment.
Glucose-dependent insulin release
Semaglutide stimulates insulin secretion only when blood glucose is elevated, and suppresses glucagon release. Because the mechanism is glucose-dependent, the risk of hypoglycemia is low compared to sulfonylureas or exogenous insulin.
What the research suggests
Semaglutide has one of the strongest randomized controlled trial records of any weight-management pharmacotherapy. The STEP trial program for obesity and the SUSTAIN program for type 2 diabetes together enrolled tens of thousands of participants across multiple continents.
Weight management (STEP program)
STEP-1 (Wilding et al., New England Journal of Medicine, 2021) was a 68-week, placebo-controlled trial of 1,961 adults without diabetes. Participants on 2.4 mg semaglutide lost a mean of 14.9% of body weight, compared with 2.4% in the placebo group. Subsequent STEP trials have tested semaglutide in adolescents, in combination with behavioral therapy, and in patients with cardiovascular disease.
Cardiovascular outcomes (SUSTAIN-6)
SUSTAIN-6 (Marso et al., New England Journal of Medicine, 2016) studied 3,297 patients with type 2 diabetes and high cardiovascular risk. Over a median 2.1 years of follow-up, semaglutide was associated with a 26% relative reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke) versus placebo.
Heart failure (STEP-HFpEF)
STEP-HFpEF (Kosiborod et al., New England Journal of Medicine, 2023) tested semaglutide in patients with obesity and heart failure with preserved ejection fraction. Compared with placebo, semaglutide improved symptom scores, exercise tolerance, and inflammatory markers over 52 weeks.
What research has not settled
Long-term outcomes beyond 4–5 years remain under investigation, particularly around weight regain after discontinuation. The STEP-4 trial (Rubino et al., JAMA, 2021) demonstrated meaningful weight regain when semaglutide was withdrawn, raising questions about how long treatment should continue. Compounded semaglutide specifically has not been studied in dedicated randomized trials — clinical inferences are drawn from the brand-name data and shared active ingredient.
Administration
Semaglutide is administered by weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. In clinical trials, dosing is titrated upward from a low starting dose (0.25 mg weekly) to the therapeutic target over roughly 16 weeks, which reduces gastrointestinal side effects during the initiation window.
Brand-name Wegovy is dosed at 2.4 mg weekly for weight management; Ozempic is dosed at 0.5–2.0 mg weekly for type 2 diabetes. Compounded protocols vary and are set by the prescribing clinician based on tolerability, goals, and response.
This is research and regulatory context, not prescribing guidance. Your clinician will determine dosing and titration based on your specific health profile.
Side effects & safety considerations
The safety profile of semaglutide is well-characterized through large randomized trials and post-marketing surveillance. It is not without risks, and some are serious.
Common side effects
Gastrointestinal effects are the most frequently reported: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In STEP-1, about 74% of the semaglutide group reported GI symptoms versus 48% of placebo. Most resolve within the first several weeks and are dose-related; slow titration is the primary mitigation.
Serious but uncommon risks
Pancreatitis has been reported in post-marketing data, though the causal relationship remains under debate. Gallbladder-related events (cholelithiasis, cholecystitis) were elevated in STEP trials. Thyroid C-cell tumor risk has been observed in rodent models and carries an FDA black-box warning on brand products; no causal signal has been confirmed in humans.
Contraindications
- •Personal or family history of medullary thyroid carcinoma
- •Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •Pregnancy or breastfeeding
- •History of pancreatitis (relative contraindication)
- •Type 1 diabetes (semaglutide is not a substitute for insulin)
Your prescribing clinician will review your medical history, medications, and goals before determining whether semaglutide is appropriate. This page is educational, not medical advice.
Brand vs. compounded: regulatory context
Brand-name semaglutide (Ozempic, Wegovy) is FDA-approved for specific indications. Compounded semaglutide is not FDA-approved — it is prepared on a patient-specific basis by licensed U.S. compounding pharmacies under the federal 503A and 503B frameworks. This is a long-standing regulatory pathway that has allowed pharmacies to prepare custom medications for decades.
From early 2022 through February 21, 2025, semaglutide appeared on the FDA drug shortage list, which provided the regulatory basis for compounding pharmacies to prepare it at scale for patients who could not access brand-name supply. FDA declared the shortage resolved on February 21, 2025. Enforcement-discretion windows permitted 503A compounding through April 22, 2025 and 503B compounding through May 22, 2025, after which the legal pathway for compounded semaglutide narrowed significantly. Current availability depends on this regulatory status and is monitored closely by your clinician and pharmacy.
Compounded medications are prepared to the clinician's specifications and quality-tested before shipping, but they have not undergone the full FDA approval process that brand-name versions have. Patients considering compounded semaglutide should understand this distinction.
Ready to see if semaglutide is right for you?
Take a 3-minute assessment. A licensed clinician reviews your health history and goals, then prescribes only if semaglutide is clinically appropriate. Shipped from licensed U.S. compounding pharmacies.
Deep dives on Semaglutide
Research-backed articles covering specific topics in depth.
Semaglutide Cost: Brand vs Compounded Pricing
Semaglutide: A comprehensive, data-driven cost comparison guide covering brand-name (Ozempic/Wegovy) vs. compounded semaglutide pricing, insurance pathw...
Semaglutide Weight Loss: How It Works & What to Expect
Semaglutide: Based on general knowledge of this keyword space: patient-centric explainer combining mechanism of action, realistic outcome timelines, and...